Reshaping heart health through pioneering genetic medicine
LEXEO Therapeutics is a clinical-stage genetic medicines company dedicated to transforming cardiovascular and CNS disease treatment through AAV-mediated gene therapy. Its pipeline targets inherited cardiac conditions including Friedreich's ataxia cardiomyopathy, arrhythmogenic cardiomyopathy, and APOE4-associated Alzheimer's disease. The company is publicly traded on NASDAQ (LXEO) and is headquartered in New York City.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountNo funding data available yet.
Know something? Help us improve our data.
Create a free account to see which investors have funded this company.
Late-stage biopharma using single-molecule tracking, AI, and engineering to discover and develop ...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
Health insurance company using technology to make health care simple, affordable, and accessible.
Global clinical research organization specializing in early-stage clinical trials and bioanalytic...
